(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2007 (28.06.2007)

PCT

(10) International Publication Number
WO 2007/071711 A3

(51) International Patent Classification:
A61K 39/09 (2006.01) *A61K 39/385* (2006.01)

(21) International Application Number:
PCT/EP2006/069979

(22) International Filing Date:
20 December 2006 (20.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0526232.4	22 December 2005 (22.12.2005)	GB
0607087.4	7 April 2006 (07.04.2006)	GB
0607088.2	7 April 2006 (07.04.2006)	GB
0609902.2	18 May 2006 (18.05.2006)	GB
0620336.8	12 October 2006 (12.10.2006)	GB
0620337.6	12 October 2006 (12.10.2006)	GB
0620815.1	19 October 2006 (19.10.2006)	GB
0620816.9	19 October 2006 (19.10.2006)	GB
PCT/GB2006/004634	12 December 2006 (12.12.2006)	GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS SA** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BIEMANS, Ralph Leon** [BE/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE). **GARCON, Nathalie Marie-Josephe** [FR/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE). **HERMAND, Philippe Vincent** [BE/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE). **POOLMAN, Jan** [NL/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE). **VAN MECHELEN, Marcelle Paulette** [BE/BE]; GlaxoSmithKline Biologicals SA, Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agents: **LUBIENSKI, Michael John** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
8 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINE

(57) Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.

WO 2007/071711 A3